Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its lead therapeutic program to treat obesity.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...